With 30+ years in the pharmaceutical and medical device industry, Dr. Sharkey possesses extensive experience in executive management, business development, pharmaceutical and medical device development, regulatory affairs and manufacturing operations covering multiple therapeutic segments.
Dr. Sharkey has been a key contributor to the development, acquisition, or divestment of multiple products with annual revenues ranging from $5 million to more than $2 billion dollars. Respected as a skillful negotiator capable of focusing the parties on relevant issues and mutual benefits, along with his extensive experience across multiple therapeutic, allows him to identify transactional structures which work for all parties involved.
Prior to his current appointment as Vice-President of Business Development for GeoVax, he served as our part-time Head of Business Development, and was primary lead for the successful completion of two transformational transactions which propelled the company into Phase 2 programs in the areas of Covid-19 and Oncology.
Previously, as CEO of Largent Health, LLC, he oversaw the development strategy for three 510(k) medical devices incorporating a proprietary antimicrobial technology, eventually leading to the registration and commercial launch of the 1st FDA cleared dental cavity cleanser with antimicrobial claims.
In 2010, Dr. Sharkey founded Cogas Consulting, LLC, a consultancy providing executive management, technical development, regulatory and business development services to small and mid-size pharma and medical device companies. He has also assisted several companies in their financing activities.
Prior to the above, he held senior executive positions within both Novartis and Shionogi and was involved in several notable partnering transactions including Novartis obtaining European rights to Lucentis® as well as global rights to Focalin® and Focalin® XR and Shionogi’s global license for Osphena®.
Dr. Sharkey holds a Ph.D. in Chemistry from the University of Buffalo and a B.S. in Chemistry from the State University of New York at Oneonta.
What is John W. Sharkey's net worth?
The estimated net worth of John W. Sharkey is at least $71.14 as of April 10th, 2025. Sharkey owns 247 shares of GeoVax Labs stock worth more than $71 as of October 12th. This net worth estimate does not reflect any other assets that Sharkey may own. Learn More about John W. Sharkey's net worth.
How do I contact John W. Sharkey?
Has John W. Sharkey been buying or selling shares of GeoVax Labs?
John W. Sharkey has not been actively trading shares of GeoVax Labs over the course of the past ninety days. Most recently, on Thursday, April 10th, John W. Sharkey bought 240 shares of GeoVax Labs stock. The stock was acquired at an average cost of $24.75 per share, with a total value of $5,940.00. Following the completion of the transaction, the vice president now directly owns 247 shares of the company's stock, valued at $6,113.25. Learn More on John W. Sharkey's trading history.
Who are GeoVax Labs' active insiders?
